Zimbabwe has rejected a significant US healthcare agreement worth 367 million US dollars (£272m) over five years due to Washington's request for confidential information.
The decision became public after a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman later clarified that the US was requesting health data for scientific study and commercial gain but refused to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated over $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for more talks to find a agreement agreeable to all parties so the country's vital HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable situation in Kenya, where a court blocked a similar health funding agreement following legal challenges were raised about the security of citizens' medical information.
After resuming office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government agreements to enhance transparency and accountability.
According to reports, 16 nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any equivalent promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery without any assurance that the end products would be available to our people should a new pandemic arise."
National Interest and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining structures already set up through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This system is intended to ensure that when a country contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage further dialogue with our US partners on how subsequent co-operation might be arranged in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts said it understood the government's concerns, but urged that talks need to persist considering much of the nation's HIV programmes depended on international support.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," it commented.
The situation highlights the complex debate between accepting much-needed foreign assistance and safeguarding local interests in an ever more data-driven world.